Acumen Pharmaceuticals (ABOS) Stock Statistics & Valuation Metrics

Acumen Pharmaceuticals has a market cap or net worth of $194.97M. The enterprise value is $140.87M.

Acumen Pharmaceuticals has 72,212,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Acumen Pharmaceuticals’s return on equity (ROE) is -1.72 and return on invested capital (ROIC) is -121.71%.

The current PE Ratio of Acumen Pharmaceuticals is ―. Acumen Pharmaceuticals’s PEG ratio is -0.06.

In the last 12 months, Acumen Pharmaceuticals had revenue of 0.00 and earned -121.33M in profits. Earnings per share was -2.00.

In the last 12 months, operating cash flow was -115.54M and capital expenditures -88.00K, giving a free cash flow of -115.63M billion.

Acumen Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Acumen Pharmaceuticals upcoming earnings date is May 19, 2026, After Close (Confirmed).

Acumen Pharmaceuticals as a current ratio of 4.07, with Debt / Equity ratio of 44.46%

In the past 12 months, Acumen Pharmaceuticals has paid 0.00 in taxes.

Acumen Pharmaceuticals EV to EBITDA ratio is -0.85, with an EV/FCF ratio of -0.91.

Acumen Pharmaceuticals has $116.86M in cash and marketable securities with $31.31M in debt, giving a net cash position of $85.55M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Acumen Pharmaceuticals is $6.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy